Search alternatives:
largest decrease » marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 3,152 for search '(( 7 ((mean decrease) OR (point decrease)) ) OR ( _ ((largest decrease) OR (larger decrease)) ))', query time: 0.41s Refine Results
  1. 1
    Table 7_Road transportation is associated with decreased intestinal motility in horses.xlsx

    Table 7_Road transportation is associated with decreased intestinal motility in horses.xlsx by Sharanne L. Raidal (3097719)

    Published 2025
    “…Horses with high heart rates, high sweat scores or abnormal demeanour on arrival demonstrated decreased intestinal motility. Salivary cortisol concentrations increased after transportation (mean difference, 95% CI, for T0 vs T1 was 1.66, 1.09−2.53 nmol/L) and were inversely associated with intestinal motility. …”
    Save to List
    Saved in:
  2. 2
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 3
    Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM.

    Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM. by Chaminda D. Gunawardene (22794593)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Naringenin decreases total cell viability.

    Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Cephalometric measurement points.

    Cephalometric measurement points. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity.

    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Mean lesion depth of the SDF test groups and the SDF-free group at baseline and post-cycling time points.

    Mean lesion depth of the SDF test groups and the SDF-free group at baseline and post-cycling time points. by Suphanida Kaewkamchai (19762172)

    Published 2024
    Save to List
    Saved in:

Search Tools: